Clinical Trial

A Study of Cardiovascular Events iN Diabetes Plus

Study acronym: ASCEND PLUS
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
ASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes, the need for any procedures to unblock or bypass an artery to their heart, and the chance of dying because of vascular problems.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-06-27; most recent amendment 2026-06-18.
Status change: Recruiting → Active, Not Recruiting 2026-06-18
Status change: Not Yet Recruiting → Recruiting 2023-03-16
Trial Details
NCT Number NCT05441267
Lead Sponsor University of Oxford
Collaborators: Novo Nordisk A/S
Conditions Diabetes Mellitus, Type 2
Enrollment 21,296 participants
Start Date 2023-03-13
Primary Completion 2028-08-17 (estimated)
Study Completion 2048-08-17 (estimated)
Updated on ClinicalTrials.gov 2026-06-23